SynthesisBMC urology2002
Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials.
Synthesis in BMC urology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS).BMJ clinical evidence · 2011Pooled it
- Finasteride for benign prostatic hyperplasia.The Cochrane database of systematic reviews · 2010Pooled it
- Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers.International journal of molecular sciences · 2025Review
- Concise Synthesis of Naphthalene-Based 14-Aza-12-Oxasteroids.Molecules (Basel, Switzerland) · 2025Article
- The effect of 5-alpha reductase inhibitors on the detection of prostate cancer with multiparametric magnetic resonance imaging and prostate biopsy.Croatian medical journal · 2024Article
- Analysis of the finasteride treatment and its withdrawal in the rat hypothalamus and hippocampus at whole-transcriptome level.Journal of endocrinological investigation · 2024Article
- Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection.Biomolecules · 2024Article
- A Novel Insight into the Immune-Related Interaction of Inflammatory Cytokines in Benign Prostatic Hyperplasia.Journal of clinical medicine · 2023Review
- Post-finasteride syndrome: An emerging clinical problem.Neurobiology of stress · 2020Article
- [Interventional treatment of benign prostatic hyperplasia : Embolization of the testicular vein].Der Radiologe · 2017Review
- Persistent erectile dysfunction in men exposed to the 5α-reductase inhibitors, finasteride, or dutasteride.PeerJ · 2017Article
- Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship?Arab journal of urology · 2016Article
- Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?Reviews in endocrine & metabolic disorders · 2015Review
- Article
- Intraethnic variation in steroid-5-alpha-reductase polymorphismsin prostate cancer patients: a potential factor implicated in 5-alpha-reductase inhibitor treatment.Journal of genetics · 2015Article
- The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression.Korean journal of urology · 2014Review
- Low intraprostatic DHT promotes the infiltration of CD8+ T cells in BPH tissues via modulation of CCL5 secretion.Mediators of inflammation · 2014Article
- A systematic review of the correlates and management of nonpremature ejaculatory dysfunction in heterosexual men.Therapeutic advances in urology · 2013Article
- Inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.Journal of endocrinological investigation · 2012Article
- Changes in sexual function in benign prostatic hyperplasia patients taking dutasteride: 1-year follow-up results.Korean journal of urology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign prostatic hyperplasia affects older men. This systematic review determined efficacy and adverse effects of finasteride. REVIEW
methodsPubMed, the Cochrane Library, reference lists of reports, and reviews were searched for randomised, double-blind trials of finasteride in benign prostatic hyperplasia. Outcomes included symptom score, urinary flow rate, prostate volume, discontinuation, and adverse effects. Relative risk and NNT or NNH were calculated for dichotomous data. Sensitivity analyses assessed influences of baseline symptom severity, initial prostate volume, a dominating trial, and previous interventions.
resultsThree trials had active controls and 19 had placebo. In placebo-controlled trials, 8820 patients received finasteride 5 mg and 5909 placebo over 3-48 months. Over 48 months finasteride produced greater improvements in total symptom score, maximum urinary flow rate, and prostate volume. Significantly more sexual dysfunction, impotence, ejaculation disorder and decreased libido occurred with finasteride at 12 months; the NNH for any sexual dysfunction at 12 months was 14. Significantly fewer men treated with finasteride experienced acute retention or had surgery at 24 or 48 months than with placebo; at 12 months the NNT was 49 (31 to 112) to avoid one acute urinary retention and 31 (21 to 61) to avoid one surgery. Sensitivity analyses showed benefit with finasteride 5 mg to be constant irrespective of the initial prostate volume.
conclusionsInformation from many patients in studies of high quality showed beneficial effects of finasteride in terms of symptoms, flow rate and prostate volume. More utility would result if patient centred outcomes were reported in dichotomous form.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.